f o r S i c k l e C e l l D i s e a s e , washington, D.C-. T h i s study was u n d e r t a k e n t o evaluate a s i m p l e and e f f icient r a d i a l immunodiffusion test system f o r q u a n t i f y i n g hemog l o b i n s S and F i n c o r d blood o f newborn infants. In e a r l i e r studies specific g o a t a n t i -S and specific r a b b i t a n t i -F sera were shown t o b e adequate f o r q u a n t i f y i n g hemoglobins S and F i n mixed p r o p o r t i o n s s i m u l a t i n g those anticipated in newborn infants w i t h hemoglobin AS o r SS. To d a t e 107 c o r d b l o o d specimens from b l a c k infants have been t e s t e d f o r r e l a t i v e q u a n t i t i e s o f hemoglobins S and F. The mean relative q u a n t i t y o f F was 86.3% * 10.6 S.D. I n 1 5 o f t h e s e specimens S was d e t e c t e d with a mean relative q u a n t i t y o f 6.3% + 2.5 S.D. T h i s t e c h n i q u e p r e s e n t l y can s e r v e as a convenient s c r e e n i n g device w i t h i d e n t i f i c a t i o n o f SS among p o s i t i v e s by t h e more cmbersome agar g e l e l e c t r o p h o r e s i s t e c h n i q u e . Continuing work w i l l compare t h e p e r c e n t concordance between d i a g n o s e s o f AS and SS by these two methods. This study was designed t o determine the origin of SF and its turnover in t h e rat and in man. The concentrotion of SF was measured by radioimmunoassay. 5 9~e in SF during kinetic studies was measured after ultracentrifugal fractionation of plasma on a sucrose gradient, based on the greater molecular weight of ferritin compared with other iron containing components. After injection of heat-treated 5 9~e -~~~ in rats, peak labelling of SF fraction was a t 30 min; other 5 9~e in plosma, primarily transferrin-bound, was maximally labelled a t 2 h. N o labelling of the SF fraction was detected after injection of 59~e-transferrin in man or in the rat or after 59~e-hemoglobin-hoptoglobin in the rat. Purified rat liver 59~e-ferritin, injected intravenously in the rat, was removed by t h e liver a t an exponential rate with a half-life of 4 min.
NEW ROLE FOR
The turnover of SF in man was estimated by a n unusual approach, based on a n 8-fold higher concentration in t h e newborn compared with the adult. SF concentration was measured in 1 0 ml increments of blood removed during 1.5 -2.0 volume exchange transfusions of the newborn for hyperbilirvbinemia. The decrease in serum SF during the 1 h exchanges was slow and of small magnitude. The rate of synthesis of SF was computed t o correspond t o a half-life a s short a s 5 min. The rapid turnover of iron in SF, compared with tmnsferrin iron, suggests a quantitatively important role for SF in t h e transport of iron from the RE cell t o the liver.
CESSATION O F THERAPY DURING REMISSION IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA (ALL). Joseph V. Simone, Rhomes
Aur, Manuel Verzosa, Omar Hustu, and Donald Pinkel, St. Jude Children's Res. Hosp., Memphis, TN. Combination chemotherapy and preventive central nervous system (CNS) therapy for childhood ALL have resulted in 5-year leukemia-free survival in about one-half of the patients. However, the risk of side effects and fatal infection is significant so chemotherapy was stopped after 2-3 years of complete remission.
Therapy was stopped in a total of 123 patients with ALL; 104 were in initial complete remission, 19 had relapsed at least once. All were treated with similar chemotherapy but differing preventive CNS therapy. None of 7 patients given 500 or 1200 rads to the craniospinal axis has relapsed after 5-7 years. Of 8 patients given no preventive CNS therapy, 6 relapsed after stopping therapy, 5 with CNS involvement. The remaining patients received 2400 rads to the cranium with intrathecal MTX or 2400 rads craniospinal irradiation. Of 85 patients irradiated between 1967 and 1970, 1 0 have relapsed, all in the first year and most of the remainder have been off therapy 2 years or more. Of 23 given irradiation in 1970-71,2 have relapsed. Thus, the frequency of relapse is 12 of 115 in patients who received preventive CNS irradiation and 6 of 8 given no preventive therapy.
We conclude: 1) in children with ALL given preventive CNS therapy and combination chemotherapy who remain in complete remission for 2-3 years, about 10.12% relapse after stoppin therapy and 2) the risk of relapse after stopping therapy is greatest in the &st year and is greater in patients given no preventive CNS therapy. (Supported by NCI Grant CA-08480 and ALSAC). Yaish. and J u l i u s Rutzky, ( I n t r . by P a u l V. Koolley, J r . ) Wm.
--Beaumont i-!oG=aT?%?;lc, :fich. and Wayne S t a t e Univ. School of ELecl., n e t r o i t , liich.
57 of 105 c a s e s of i d i o p a t h i c t h r o n l~o c y t o p e n i c p u r r u r a (ITP) \.rere s e e n d u r i n p t h e f i r s t tcrc weeks of i l . l n e s s and e v a l u a t e d f o r response t o therap:, and e a r l y i n d i c a t o r s of c h r o n i c i t y . The h i~h i r x i d e n c e of c h r o n i c i t v aconp c h i l d r e n over t e n y e a r s of aCe (t7L) u~a s s i p n i f i c a n t l y d i f f e r e n t (p l e s s t h a n .01) from tile correspondinp i n c i d e n c e f o r c h i l d r e n t e n y e a r s of ape and younper ( b y ) . T h i s d i f f e r e n c e was unre-.
l a t e d t o s c x , i n i t i a l p l a t e l e t c o u n t , p r e c i p i t a t i n p f a c t o r o r therapy. Among t h e 48 p a t i e n t s ter, y e a r s of a r e o r youncer, e a r l v c o r t i c o s t e r o i d t h e r a p y , f o r c o n s i d e r a t i o n s b e l i e v e d t o r e p r e s e n t i n c r e a s e d ris!;, r e s u l t e d i n a s i p i f i c a n t l y g r e a t e r p o r t i o n of t h e t r e a t e d group (33X) a c h i e v i n r r e r i s s i o n b e f o r e two vleelcs i r o n o n s e t than of t h e u n t r e a t e d groun (5%), (p l e s s than .35).
The d i f f e r e n c e was a p p a r e n t when tjme t o r e r r i s s i o n was c a l c u l a t e d from tile h i s t o r i c a l o n s e t of s y~~t o r a t o l o p y r a t h e r t h a n f r o c t i c e of p r e s e n t a t i o n . I n c i d e n c e o f chronjc i t y was n o t s i r n i f i c a n t l y d i f f e r e n t ( p n e a t e r t h a n 0.5) between t h e s e ~r o u p s . Ci 7 c h r o n i c p a t i e n t s wllo r e s p o n d e i t o s t e r o i d s i n i t i a l l y and t h e n rel.apserl, a 1 1 had s o r e r e s y o n s e t o a subsequent c o u r s e . No c h r o n i c p n t ? e n t t r e a t e d w i t h cort3co-s t e r o i d s a l o n e had a s u s t a i n e d reci.;sion.
E o f 11 (73Z) c h r o n i c p a t i e n t s had a s u s t a i r c r l r e n i s s i o n a f t e r s r l e n e c t o r y . U p s t a t e Medical Center, Syracuse, New York. 2,3-DPG l e v e l s i n 1 7 p a t i e n t s w i t h n e p h r o t i c syndrome r e -J e t i n j e c t i o n of a n e s t h e s i a has been employed f o r d e n t a l c e i v i n g c h r o n i c p r e a n i s o n e t h e r a p y (51622213 nmoles/ml r b c , procedures and i s s a i d t o b e a s s o c i a t e d w i t h l e s s p a i n t h a n mean3.E.M.) were s i g n i f i c a n t l y h i g h e r t h a n i n 20 c o n t r o l s n e e d l e and s y r i n g e t e c h n i q u e s . To d e t e r m i n e i t s u s e f u l n e s s (4527+146) w i t h n e p h r o t i c syndrome n o t r e c e i v i n g prednisone f o r bone marrow a s p i r a t i o n s , t h e Syrijet-Mark I1 was used t o p . 0 .
There was a s i g n i f i c a n t c o r r e l a t i o n (r=.8826) bed e l i v e r 0 . 3 5~~ of 2% z y l o c a i n e a t 2600 p s i t o t h e p o s t e r i o r tween d o s e and 2,3-DPG l e v e l . The a c u t e e f f e c t of p r e d n i s o n e i l i a c c r e s t i n 5 0 a s p i r a t i o n s o n 27 s u b j e c t s , a g e s 4-17, w i t h was s t u d i e d i n 1 0 p a t i e n t s w i t h a c u t e leukemia i n r e m i s s i o n leukemia. A comparison was made w i t h p r i o r marrow a s p i r aundergoing p r e d n i s o n e and v i n c r i s t i n e r e i n d u c t i o n . A 21% t i o n s u s i n g 25g n e e d l e and 2-3 c c of 2% z y l o c a i n e t o s k i n and i n c r e a s e i n 2,3-DPG (p(.02) was demonstrated 3 weeks a f t e r periosteum. I n t h i s group, t h e p e r i o s t e a l d e p t h ( s k i n t o s t a r t i n g prednisone, which r e t u r n e d t o pre-treatment l e v e l s bone) was 3-15mm (mean 7). Skin wheals v a r i e d from 0 -l h 2-3 weeks a f t e r t h e r a p y was d i s c o n t i n u e d . (See Table) (mean 4.7). I n 22/50 p r o c e d u r e s (44x1, no p a i n was f e l t ; i n Before Prednisone Therapy Off Therapy 22/50 s l i g h t p a i n (44%) was f e l t b u t l e s s t h a n w i t h n e e d l e No s i g n i f i c a n t changes o c c u r r e d i n hemoglobin o r serum i n o r -(82%), no p a i n was f e l t and i n 9/50 (18%), m i l d p a i n o n l y . g a n i c phosphate l e v e l s d u r i n g p r e d n i s o n e therapy. Three paOn i n s e r t i o n of t h e n e e d l e through periosteum i n t o bone, no t i e n t s t r e a t e d w i t h v i n c r i s t i n e a l o n e demonstrated no change p a i n o r s i g n i f i c a n t l y l e s s p a i n t h a n w i t h n e e d l e i n j e c t i o n i n t h e i r 2.3-DPG l e v e l s . S i n c e a n e l e v a t i o n i n 2,3-DPG of was f e l t i n 31/50 p r o c e d u r e s (62%); e q u i v a l e n t p a i n o c c u r r e d 430 nmoles/ml r b c r e s u l t s i n a n i n c r e a s e of P50 of 1 m. Hg, i n 16/50 (32%): and more p a i n i n 3/50 (6%). I n o n l y 4/50 t h i s s t u d y p r o v i d e s evidence t h a t Hb-02 a f f i n i t y c a n b e p a t i e n t s (8%), was t h e non-jet t e c h n i q u e p r e f e r r e d . S k i n p h a r m a c o l o g i c a l l y manipulated i n t h e d i r e c t i o n of s i g n i f iwheal s i z e and p e r i o s t e a l d e p t h had no r e l a t i o n s h i p t o c a n t l y i n c r e a s e d oxygen d e l i v e r y t o t i s s u e s , and t h a t t h i s p a t i e n t response. J e t i n j e c t i o n of a n e s t h e s i a is r a p i d and e f f e c t is t i m e and d o s e r e l a t e d .
e f f e c t i v e l y r e l i e v e s t h e p a i n of marrow a s p i r a t i o n s .
409/135
i n j e c t i o n ; i n 6/50 (12%), p a i n e q u i v a l e n t t o t h e n e e d l e tech-4 8 1 5 5 9 9 n i q u e o c c u r r e d and i n none was more p a i n f e l t . On i n s e r t i o n of t h e bone marrow n e e d l e t h r o u g h s k i n i n 41/50 p r o c e d u r e s
